On CNBC's "Mad Money Lightning Round," Jim Cramer said IonQ, Inc. IONQ is "so high," and it's also losing so much money." He added that it's "too speculative" for him. As per the recent news, IonQ, on May 23, formed a strategic partnership with the Korea Institute of Science and Technology Information, or KISTI, to advance South Korea's quantum technology goals. Oklo Inc. OKLO is "literally five years behind GE Vernova GEV," Cramer said. "I don't have the time for that when I can just go buy GE Vernova." Ve ...

Macy's, Inc. M will release its first-quarter earnings results before the opening bell on Wednesday, May 28. Analysts expect the New York-based company to report quarterly earnings at 15 cents per share, down from 27 cents per share in the year-ago period. According to data from Benzinga Pro, Macy's projects to report quarterly revenue at $4.43 billion, compared to $4.85 billion a year earlier. On May 16, the company's board of directors declared a regular quarterly dividend of 18.24 cents per share. Macy's ...

Abercrombie & Fitch Co. ANF will release its first-quarter earnings results before the opening bell on Wednesday, May 28.Analysts expect the New Albany, Ohio-based company to report quarterly earnings at $1.33 per share, down from $2.14 per share in the year-ago period. According to data from Benzinga Pro, Abercrombie & Fitch projects to report quarterly revenue at $1.06 billion, compared to $1.02 billion a year earlier.On March 5, the company reported fourth-quarter adjusted earnings per share of $3.57, be ...

公司动态 - Teva Pharmaceutical与Biolojic Design宣布启动BD9的IND-enabling研究 BD9是一种同时靶向TSLP和IL-13的双特异性多体药物 [1] - Teva获得BD9的独家开发权 用于治疗TH2驱动的炎症性疾病如特应性皮炎和哮喘 [1] - BD9通过同时阻断TH2驱动的两个关键炎症因子 有望改善现有疗法效果不佳的特应性皮炎和哮喘患者预后 [2] - IND-enabling研究的启动标志着该科学创新向潜在治疗选择转化的关键里程碑 为临床试验铺平道路 [3] - 根据协议 Teva负责BD9的全球开发 Biolojic有资格获得基于临床前、临床、监管和商业化里程碑的付款 [4] 产品进展 - 5月美国FDA批准Teva与Alvotech的Selarsdi(ustekinumab-aekn)注射剂 可作为强生Stelara(ustekinumab)的生物类似药互换使用 [4] - 1月美国FDA发布关于醋酸格拉替雷(glatiramer acetate)可能引发罕见但严重过敏反应(过敏性休克)的警告 该药物由Teva以Copaxone品牌名销售 用于治疗多发性硬化症复发 [5] 法律事务 - 2月Axsome Therapeutics与Teva达成和解协议 解决关于Axsome抗抑郁药Auvelity的所有专利诉讼 [6] - 诉讼源于Teva向FDA提交简略新药申请 寻求在Axsome相关专利到期前在美国销售Auvelity的仿制药 [7] 市场表现 - Teva股价周二上涨6.01% 报收17.98美元 [7]

Canaccord Genuity analyst Susan Anderson reiterated the Buy rating on e.l.f. Beauty ELF with a price forecast of $105.On May 23, the firm disclosed via social media its plan to increase prices by $1 starting August 1, attributing the decision to the current tariff environment.According to Anderson, this development should be viewed positively, as it suggests the company’s tariff impact is ‘manageable’ using its existing strategy while continuing to provide affordable, high-quality products.Also Read: ‘Big S ...

Savara Inc. SVRA on Tuesday announced that it received a U.S. Food And Drug Administration (FDA) refusal To File (RTF)) letter regarding the Biologic license application (BLA) for Molbreevi, a therapy for treating patients with autoimmune Pulmonary Alveolar Proteinosis (PAP).Autoimmune PAP is a rare lung disease characterized by the abnormal build-up of surfactant in the lungs’ alveoli.Surfactant consists of proteins and lipids and is an important physiological substance that lines the alveoli to prevent th ...

Bank of America Securities analyst Sara Senatore explained that while the restaurant industry may seem simple due to its familiarity with consumers, investing in restaurant stocks remains complex, given the wide performance variation within the sector.According to Senatore, in today’s value-conscious environment, the restaurants seeing success are those offering standout products and experiences across multiple dimensions.This consistent execution has allowed leading quick-service pizza chains to expand mar ...

收购SiteOne Therapeutics - 公司同意收购专注于开发钠通道小分子抑制剂的生物技术公司SiteOne Therapeutics 以治疗疼痛和其他神经元过度兴奋性疾病 [1] - 交易包括处于2期临床阶段的Nav1 8抑制剂STC-004 该药物可能成为慢性疼痛患者的下一代非阿片类疗法 [1] - 收购总金额最高可达10亿美元 包括预付款和后续基于监管及商业里程碑的付款 [2] 慢性疼痛治疗领域 - 全球慢性疼痛负担持续增加 目前仍缺乏有效的非阿片类治疗方案 [2] - 公司计划继续开发STC-004 作为推进无成瘾性疼痛疗法的一部分 [2] 近期研发合作动态 - 5月公司与韩国生物制药公司Rznomics达成战略合作 专注于利用RNA编辑技术开发疗法 [3] - 若行使全部选择权 该合作总价值可能超过13亿美元 外加产品销售特许权使用费 [4] 市场反应 - 消息公布后公司股价上涨1 7%至726 14美元 [4]

B of A Securities analyst Wamsi Mohan revised full-year estimates for Pure Storage, Inc. PSTG ahead of its earnings release on May 28.The analyst forecasts first quarter fiscal 2026 revenue and EPS at $772 million and 26 cents, respectively, slightly ahead of Street expectations of $770 million and 25 cents.The analyst highlighted that the first quarter is typically the company’s weakest from a seasonal perspective. Historically, since 2016, the first quarter has shown an average sequential revenue decline ...

JP Morgan analyst Harlan Sur maintained an Overweight rating on Marvell Technology, Inc. MRVL with a price forecast of $130 on Tuesday.This price forecast is based on Marvell’s strong market leadership in optical connectivity, synergies with its Storage, Networking, and embedded processing franchises, and its solid growth outlook in AI/Networking, Sur asserted.Marvell will report earnings on Thursday, and Sur expects a continued volume ramp of Amazon.Com, Inc. AMZN Trainium 2 ASIC and Alphabet Inc. GOOGL GO ...